Implications of cardiac markers in risk-stratification and management for COVID-19 patients
Pengping Li(The First People's Hospital of Xiaoshan District, Hangzhou), Hongshan Chen(Tianjin Medical University General Hospital), Xinyi Xia(Nanjing General Hospital of Nanjing Military Command), Yong Ji(Nanjing Medical University), Bin Huang(Nanfang Hospital), Kening Li(Jiangsu Cancer Hospital), Xin Tang(Nanjing University of Chinese Medicine), Wenhua You(Nanjing Medical University), Weiwei Duan(Nanjing Medical University), Mengyan Zhu(Nanjing Agricultural University), Yuan Liang(Wuhan Institute of Technology), Xin Wang(Qingdao National Laboratory for Marine Science and Technology), Tingting Zhang(Guangzhou Medical University), Ziyu Wang(Nanjing Medical University), Jie Li(Nanjing University of Chinese Medicine), Xuesong Li(Peking University), Hong Yan(Second Affiliated Hospital of Nanjing Medical University), Wei Wu(Tokyo Medical University), Yi Han(Jiangsu Province Hospital), Han Shen(Nanjing Drum Tower Hospital), Rong Ding(Jiangsu Cancer Hospital), Lingxiang Wu(Shanghai Research Center for Acupuncture and Meridians), Qianghu Wang(Jiangsu Cancer Hospital)
Cited by 22
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis
|Journal of Medical Virology|2020|1.6k
Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells
|Cell Reports|2022|465